OncoTherapy Science (4564.T) Stock Price

OncoTherapy Science Price

JPX·CLOSED
19.00JPY-1.00 (-5.13 %)
Market closed

Revenue at OncoTherapy Science has contracted by 2.3% per year over the past 19 years to 750.05 M JPY. Earnings per share have grown at 69.5% per year over the last 3 years. OncoTherapy Science's net margin stands at -108.7%, up from -469.7% several years earlier. The stock trades about 6% above its 52-week low.

OncoTherapy Science stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of OncoTherapy Science over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how OncoTherapy Science stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing OncoTherapy Science's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

OncoTherapy Science Stock Price History
DateOncoTherapy Science Price
8/12/202619.00 JPY
8/10/202620.00 JPY
8/7/202620.00 JPY
8/6/202619.00 JPY
8/5/202619.00 JPY
8/4/202619.00 JPY
8/3/202620.00 JPY
7/31/202619.00 JPY
7/30/202619.00 JPY
7/29/202620.00 JPY
7/28/202620.00 JPY
7/27/202620.00 JPY
7/24/202621.00 JPY
7/23/202620.00 JPY
7/22/202619.00 JPY
7/21/202621.00 JPY
7/17/202619.00 JPY
7/16/202621.00 JPY
7/15/202620.00 JPY
7/14/202620.00 JPY
7/13/202620.00 JPY
7/10/202620.00 JPY
7/9/202619.00 JPY
7/8/202619.00 JPY
7/7/202621.00 JPY
7/6/202620.00 JPY
7/3/202619.00 JPY
7/2/202619.00 JPY
7/1/202619.00 JPY
6/30/202618.00 JPY
6/29/202619.00 JPY
6/26/202619.00 JPY
6/25/202619.00 JPY
6/24/202619.00 JPY
6/23/202620.00 JPY
6/22/202619.00 JPY
6/19/202621.00 JPY
6/18/202621.00 JPY
6/17/202620.00 JPY
6/16/202619.00 JPY
6/15/202620.00 JPY
6/12/202619.00 JPY
6/11/202619.00 JPY
6/10/202619.00 JPY
6/9/202619.00 JPY
6/8/202619.00 JPY
6/5/202619.00 JPY
6/4/202619.00 JPY
6/3/202620.00 JPY
6/2/202621.00 JPY
6/1/202621.00 JPY
5/29/202622.00 JPY
5/28/202621.00 JPY
5/27/202621.00 JPY
5/26/202621.00 JPY
5/25/202622.00 JPY
5/22/202622.00 JPY
5/21/202620.00 JPY
5/20/202620.00 JPY
5/19/202620.00 JPY
5/18/202620.00 JPY
5/15/202620.00 JPY
5/14/202621.00 JPY
5/13/202621.00 JPY
5/12/202621.00 JPY
5/11/202621.00 JPY
5/8/202624.00 JPY
5/7/202623.00 JPY
5/1/202623.00 JPY
4/30/202624.00 JPY
4/28/202624.00 JPY
4/27/202624.00 JPY
4/24/202624.00 JPY
4/23/202625.00 JPY
4/22/202626.00 JPY
4/21/202627.00 JPY
4/20/202631.00 JPY
4/17/202627.00 JPY
4/16/202629.00 JPY
4/15/202626.00 JPY
4/14/202626.00 JPY
4/13/202624.00 JPY
4/10/202623.00 JPY
4/9/202625.00 JPY
4/8/202627.00 JPY
4/7/202627.00 JPY
4/6/202625.00 JPY
4/3/202624.00 JPY
3/27/202622.00 JPY
3/26/202621.00 JPY
3/25/202621.00 JPY
3/24/202621.00 JPY
3/23/202621.00 JPY
3/19/202623.00 JPY
3/18/202623.00 JPY
3/17/202623.00 JPY
3/16/202623.00 JPY
3/13/202622.00 JPY
3/12/202623.00 JPY
3/11/202623.00 JPY
3/9/202621.00 JPY
3/6/202621.00 JPY
3/5/202620.00 JPY
2/27/202621.00 JPY
2/26/202621.00 JPY
2/25/202620.00 JPY
2/20/202621.00 JPY
2/19/202621.00 JPY
2/18/202621.00 JPY
2/17/202621.00 JPY
2/16/202621.00 JPY
2/13/202621.00 JPY
2/12/202620.00 JPY
2/10/202620.00 JPY
2/9/202620.00 JPY
2/6/202620.00 JPY
2/5/202620.00 JPY
2/4/202620.00 JPY
2/3/202620.00 JPY
2/2/202620.00 JPY
1/30/202620.00 JPY
1/29/202620.00 JPY
1/28/202621.00 JPY
1/27/202621.00 JPY
1/26/202622.00 JPY
1/23/202621.00 JPY
1/22/202621.00 JPY
1/21/202622.00 JPY
1/20/202622.00 JPY
1/19/202622.00 JPY
1/16/202623.00 JPY
1/15/202623.00 JPY
1/14/202622.00 JPY
1/13/202623.00 JPY
1/9/202624.00 JPY
1/8/202623.00 JPY
1/7/202621.00 JPY
1/6/202621.00 JPY
1/5/202621.00 JPY
12/30/202520.00 JPY
12/29/202520.00 JPY
12/26/202520.00 JPY
12/25/202521.00 JPY
12/24/202521.00 JPY
12/23/202520.00 JPY
12/22/202520.00 JPY
12/19/202520.00 JPY
12/18/202521.00 JPY
12/17/202521.00 JPY
12/16/202521.00 JPY
12/15/202521.00 JPY
12/12/202521.00 JPY
12/11/202522.00 JPY
12/10/202522.00 JPY
12/9/202520.00 JPY
12/8/202520.00 JPY
12/5/202521.00 JPY
12/4/202522.00 JPY
12/3/202521.00 JPY
12/2/202522.00 JPY
12/1/202522.00 JPY
11/28/202522.00 JPY
11/27/202520.00 JPY
11/26/202520.00 JPY
11/25/202520.00 JPY
11/21/202521.00 JPY
11/20/202521.00 JPY
11/19/202522.00 JPY
11/18/202522.00 JPY
11/17/202523.00 JPY
11/14/202524.00 JPY
11/13/202524.00 JPY
11/12/202524.00 JPY
11/11/202524.00 JPY
11/10/202524.00 JPY
11/7/202524.00 JPY
11/6/202524.00 JPY
11/5/202523.00 JPY
11/4/202524.00 JPY
10/31/202524.00 JPY
10/30/202523.00 JPY
10/29/202523.00 JPY
10/28/202524.00 JPY
10/27/202524.00 JPY
10/24/202525.00 JPY
10/23/202525.00 JPY
10/22/202524.00 JPY
10/21/202523.00 JPY
10/20/202524.00 JPY
10/17/202523.00 JPY
10/16/202523.00 JPY
10/15/202524.00 JPY
10/14/202522.00 JPY
10/10/202522.00 JPY
10/9/202523.00 JPY
10/8/202522.00 JPY
10/7/202523.00 JPY
10/6/202524.00 JPY
10/3/202524.00 JPY
10/2/202525.00 JPY
10/1/202523.00 JPY
9/30/202526.00 JPY
9/29/202526.00 JPY
9/26/202526.00 JPY
9/25/202527.00 JPY
9/24/202529.00 JPY
9/22/202528.00 JPY
9/19/202526.00 JPY
9/18/202526.00 JPY
9/17/202526.00 JPY
9/16/202526.00 JPY
9/12/202526.00 JPY
9/11/202525.00 JPY
9/10/202526.00 JPY
9/9/202526.00 JPY
9/8/202529.00 JPY
9/5/202529.00 JPY
9/4/202532.00 JPY
9/3/202530.00 JPY
9/2/202529.00 JPY
9/1/202528.00 JPY
8/29/202528.00 JPY
8/28/202528.00 JPY
8/27/202528.00 JPY
8/26/202528.00 JPY
8/25/202528.00 JPY
8/22/202527.00 JPY
8/21/202527.00 JPY
8/20/202528.00 JPY
8/19/202527.00 JPY
8/18/202526.00 JPY
8/15/202526.00 JPY
8/14/202528.00 JPY
8/13/202527.00 JPY
Access this data via the Eulerpool API
Get Free API Key

OncoTherapy Science Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
211.25 M JPY
-2.99 B JPY
-2.85 B JPY
Jan 1, 2019
280.59 M JPY
-2.95 B JPY
-2.93 B JPY
Jan 1, 2020
316.22 M JPY
-2.19 B JPY
-2.24 B JPY
Jan 1, 2021
332.48 M JPY
-1.64 B JPY
-1.56 B JPY
Jan 1, 2022
1.15 B JPY
-2.05 B JPY
-2.57 B JPY
Jan 1, 2023
1.13 B JPY
-1.11 B JPY
-1.12 B JPY
Jan 1, 2024
610.12 M JPY
-1.12 B JPY
-1.29 B JPY
Jan 1, 2025
750.05 M JPY
-797.94 M JPY
-815.29 M JPY

OncoTherapy Science Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 6:02 PM
 
REVENUEB JPY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB JPY
EBITB JPY
EBIT MARGIN%
NET INCOMEB JPY
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
5.265.366.223.281.020.770.270.290.210.280.320.331.151.130.610.75
58.011.9816.08-47.34-68.97-24.39-65.417.52-26.2232.7012.865.06247.29-1.65-46.2122.95
12.9411.3424.23-0.37-1.18-1.56-4.51-4.20-5.69-4.29-15.825.729.803.62-29.02-1.60
0.680.611.51-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.050.020.110.04-0.18-0.01
0.330.221.18-1.11-3.79-1.96-2.98-3.00-2.99-2.95-2.19-1.64-2.05-1.11-1.12-0.80
6.324.1619.03-33.96-372.17-255.14-1,120.30-1,050.35-1,416.11-1,054.64-692.72-493.07-177.97-97.53-183.61-106.27
0.510.570.73-1.10-3.68-1.33-2.79-3.00-2.85-2.93-2.24-1.56-2.57-1.12-1.29-0.82
244.5910.9828.45-251.72233.27-63.71109.007.68-5.032.91-23.72-30.2564.70-56.5115.21-36.72
117.70118.20117.30107.90130.40146.79147.00147.03147.03147.50163.05176.26187.47192.64212.78261.14
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales OncoTherapy Science generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue OncoTherapy Science retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare OncoTherapy Science's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares OncoTherapy Science has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against OncoTherapy Science's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

OncoTherapy Science stock margins

The OncoTherapy Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OncoTherapy Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OncoTherapy Science.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
-1.70 %
-1,414.71 %
-1,349.62 %
Jan 1, 2019
-1.70 %
-1,052.72 %
-1,046.01 %
Jan 1, 2020
-15.85 %
-692.46 %
-707.92 %
Jan 1, 2021
5.88 %
-492.65 %
-469.70 %
Jan 1, 2022
9.87 %
-177.92 %
-222.90 %
Jan 1, 2023
3.67 %
-97.49 %
-98.57 %
Jan 1, 2024
-29.13 %
-183.70 %
-211.13 %
Jan 1, 2025
-1.70 %
-106.38 %
-108.70 %

OncoTherapy Science Stock Revenue, EBIT, Earnings per Share

The OncoTherapy Science earnings per share therefore indicates how much revenue OncoTherapy Science has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
1.44 JPY
-20.33 JPY
-19.39 JPY
Jan 1, 2019
1.90 JPY
-20.03 JPY
-19.90 JPY
Jan 1, 2020
1.94 JPY
-13.43 JPY
-13.73 JPY
Jan 1, 2021
1.89 JPY
-9.29 JPY
-8.86 JPY
Jan 1, 2022
6.15 JPY
-10.95 JPY
-13.72 JPY
Jan 1, 2023
5.89 JPY
-5.74 JPY
-5.81 JPY
Jan 1, 2024
2.87 JPY
-5.27 JPY
-6.05 JPY
Jan 1, 2025
2.87 JPY
-3.06 JPY
-3.12 JPY

OncoTherapy Science business model & stock analysis

OncoTherapy Science Inc is a rising company that focuses on the research and development of novel cancer therapies. The company takes pride in being able to combine the latest scientific findings with cutting-edge technologies to develop highly effective drugs and therapies that can improve the lives of cancer patients. The company is based in Japan and was founded in 2001. Since its inception, it has become one of the leading companies in cancer research and its products are available worldwide. OncoTherapy Science Inc's business model is based on the development and commercialization of new innovative cancer therapies. The company utilizes the latest technologies and research findings to achieve groundbreaking advancements in cancer treatment. These innovative therapies have the potential to improve the survival and quality of life of cancer patients. OncoTherapy Science Inc divides its activities into various areas. This includes the research and development of drugs, the clinical testing of new therapies, and the production and commercialization of cancer therapies. The research and development of new drugs form the core of OncoTherapy Science Inc's activities. The company continuously invests in researching new treatment approaches to improve the effectiveness and safety of cancer therapies. Advanced technologies such as genome sequencing and molecular diagnostics are utilized to develop personalized therapies tailored to specific types of cancer and patients. OncoTherapy Science Inc also conducts extensive clinical trials to evaluate the effectiveness and safety of its therapies. The success rate of clinical studies is very high, and many of the therapies have already received approval from regulatory authorities. Another important area of OncoTherapy Science Inc is the production and commercialization of cancer therapies. The company works closely with its distribution partners to ensure that its products are available in many countries and regions. OncoTherapy Science Inc's therapies are recommended by many oncologists and used in leading clinical institutions worldwide. Products of OncoTherapy Science Inc include a range of innovative cancer therapies. These include antibody-based drugs, immunotherapies, RNA-based therapies, and chemotherapy. These therapies have the potential to improve the effectiveness of cancer treatment and enhance the quality of life of cancer patients. An example of an innovative therapy by OncoTherapy Science Inc is OTS964, a new chemotherapeutic agent for the treatment of pancreatic cancer and other cancers. OTS964 inhibits the enzyme TOPK, which is overexpressed in many types of cancer, leading to the death of cancer cells. This therapy has shown promising results in animal models and is currently being tested in clinical trials. OncoTherapy Science Inc aims to contribute to improving the quality of life of cancer patients. The company relies on a combination of innovative research, state-of-the-art technology, and close collaboration with other industry stakeholders to achieve a leading position in cancer research. With its strong market position and commitment to cancer research, OncoTherapy Science Inc is a company that will achieve much in the future.

OncoTherapy Science SWOT Analysis

Strengths

OncoTherapy Science Inc has a strong reputation for its innovative research and development efforts, continuously pushing boundaries in the field of oncology.

The company's commitment to staying at the forefront of scientific advancements enables it to develop groundbreaking therapies that could revolutionize cancer treatment.

OncoTherapy Science Inc possesses a robust intellectual property portfolio, safeguarding its innovative discoveries and ensuring exclusivity in the market.

This intellectual property gives the company a competitive advantage, attracting potential partners and investors who seek to benefit from its proprietary technologies.

Weaknesses

Despite its strengths, OncoTherapy Science Inc currently faces challenges in establishing a significant market presence.

The company may struggle to effectively commercialize its therapies due to limited brand recognition and a comparatively smaller market share compared to established competitors.

OncoTherapy Science Inc heavily relies on research funding to sustain its operations and drive innovation.

Any disruption or reduction in funding sources can affect the company's ability to advance its research programs and develop new therapies, potentially hindering its growth.

Opportunities

The increasing prevalence of cancer worldwide presents a significant opportunity for OncoTherapy Science Inc.

As the demand for more effective and personalized cancer treatments continues to rise, the company's innovative therapies have the potential to address unmet medical needs and capture a larger market share.

OncoTherapy Science Inc can explore strategic collaborations and partnerships with other pharmaceutical companies, academic institutions, and research centers.

Such collaborations can provide access to additional resources, expertise, and financial support, facilitating accelerated development and commercialization of its therapies.

Threats

The oncology market is highly competitive, with numerous established pharmaceutical companies actively researching and developing cancer treatments.

OncoTherapy Science Inc must navigate this competitive landscape, facing challenges in gaining market share and differentiating its offerings from those of larger, well-known competitors.

The regulatory complexities and stringent compliance requirements surrounding drug development and commercialization pose potential threats to OncoTherapy Science Inc.

Non-compliance or delays in obtaining necessary approvals can impede the company's ability to bring its therapies to market in a timely manner, impacting its revenue generation and overall success.

OncoTherapy Science Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

OncoTherapy Science historical P/E ratio, EBIT multiple, and P/S ratio

OncoTherapy Science annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

OncoTherapy Science shares outstanding

The number of shares of OncoTherapy Science was 261.14 M in 2025. This indicates how many shares OncoTherapy Science is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
147.03 M Stocks
Jan 1, 2019
147.50 M Stocks
Jan 1, 2020
163.05 M Stocks
Jan 1, 2021
176.26 M Stocks
Jan 1, 2022
187.47 M Stocks
Jan 1, 2023
192.64 M Stocks
Jan 1, 2024
212.78 M Stocks
Jan 1, 2025
261.14 M Stocks

OncoTherapy Science stock splits

In OncoTherapy Science's history, there have been no stock splits.
Price targets and forecasts for OncoTherapy Science are not yet available.

OncoTherapy Science Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
11/2/2012-JPY-812.00 MJPY-2013 Q2
8/3/2012-JPY-710.50 MJPY-2013 Q1
5/14/2012-JPY-4.41 BJPY-2012 Q4
2/3/2012-JPY-590.73 MJPY-2012 Q3

OncoTherapy Science shareholder structure

% Name
1.90068%
Long Corridor Asset Management Limited
Long Corridor Asset Management Limited
0.32744%
Simplex Asset Management Co., Ltd.
Simplex Asset Management Co., Ltd.

OncoTherapy Science Beneficial Ownership Filings (SEC 13D/G)

Free Float
91.3%
Float Shares
-
Shares Outstanding
-

OncoTherapy Science Executives and Management Board

7 members · avg. age 60 · 0 % women

Management

JP

Mr. Jaehyun Park (47)

President, Chief Executive Officer, Chief Scientific Officer, President of Subsidiary, Representative Director · since 2018

–
ON

Mr. Osamu Ninomiya

Chief Director of Administration · since 2022

–

Board of Directors

HK

Mr. Hatsuo Kato (79)

Chairman of the Board · since 2020

–
JS

Mr. Junichi Shimada (61)

Director

–
TK

Mr. Toyomasa Katagiri (57)

Independent Director

–
YK

Mr. Yuichi Komine (51)

Independent Director

–
YM

Mr. Yoshio Miki (66)

Independent Director

–

OncoTherapy Science Supply Chain

OncoTherapy Science Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
5 companies
#Nameβ 1YTrend
1
Theragen Etex
Supplier·Customer·Pharmaceuticals·KR
-0.04
0.54
0.26
0.68
0.89
0.84
—
2
CrystalGenomics
Supplier·Customer·Biotechnology·KR
0.35
0.49
0.20
0.67
0.79
0.80
—
3
Cosmo Bio
Supplier·Health Care Providers & Services·JP
0.81
-0.02
0.18
0.55
0.76
0.68
—
#Nameβ 1YTrend
1
Shionogi
Supplier·Customer·Pharmaceuticals·JP
0.36
0.39
0.23
0.56
-0.67
-0.72
-0.27
2
Kyowa Kirin
Supplier·Customer·Pharmaceuticals·JP
0.29
0.03
0.24
0.68
0.79
-0.25
0.42

Frequently asked questions about OncoTherapy Science

The business model of OncoTherapy Science Inc revolves around developing cutting-edge therapies for cancer treatment. The company focuses on leveraging its innovative technologies and expertise in molecular biology to discover and develop novel drugs targeting cancer cells. OncoTherapy Science Inc aims to improve patient outcomes by advancing precision medicine through personalized therapies. By analyzing the genetic makeup of tumor cells, the company identifies specific targets and develops therapeutics to inhibit their growth. With a strong emphasis on research and development, OncoTherapy Science Inc strives to bring breakthrough treatments to market, offering hope to cancer patients worldwide.

OncoTherapy Science Inc is primarily active in the biotechnology industry.

The main competitors of OncoTherapy Science Inc in the market include pharmaceutical companies such as Pfizer, Merck & Co., and Novartis.

OncoTherapy Science Inc is a leading biotechnology company specializing in innovative cancer therapies. With a rich history spanning several successful years, OncoTherapy Science Inc has consistently demonstrated its commitment to revolutionizing cancer treatment through cutting-edge research and development. The company has a strong background in targeted therapies, utilizing advanced techniques to understand and combat the complex mechanisms of cancer. OncoTherapy Science Inc prioritizes patient-centric approaches, seeking to improve clinical outcomes and ultimately save lives. Their dedicated team of scientists and researchers are relentlessly working towards discovering breakthrough treatments for various types of cancer, cementing their position as a trusted leader in the field of oncology.

OncoTherapy Science Inc, a leading biotechnology company, has achieved several significant milestones in its journey. The company's dedication to cutting-edge research and innovation has resulted in remarkable achievements. OncoTherapy Science Inc has successfully developed and commercialized groundbreaking therapies for various types of cancers, revolutionizing the treatment landscape. Moreover, the company has received multiple accolades for its exceptional contributions to the field of oncology. OncoTherapy Science Inc's relentless pursuit of excellence has positioned it as a key player in the fight against cancer, making it a trusted name in the industry. With numerous achievements under its belt, OncoTherapy Science Inc continues to pave the way for advancements in cancer treatment.

OncoTherapy Science Inc is primarily present in Japan.

OncoTherapy Science Inc represents values of innovation, integrity, and commitment to advancing cancer treatments. The company's corporate philosophy revolves around conducting groundbreaking research to develop effective therapies for oncology patients. With a focus on precision medicine, OncoTherapy Science Inc aims to deliver personalized and targeted treatments for individuals battling cancer. Their dedication to scientific excellence, collaboration with key stakeholders, and patient-centric approach sets them apart in the field of oncology. OncoTherapy Science Inc's commitment to improving patient outcomes and revolutionizing cancer care aligns with their vision of becoming a global leader in precision oncology.

Converted at the current exchange rate, the OncoTherapy Science share trades at 0.10 EUR (19.00 JPY).

The OncoTherapy Science share (4564.T) is listed on 3 stock exchanges, including: Frankfurt (30O.F), München (30O.MU).

OncoTherapy Science Inc. is a leading biopharmaceutical company focused on the development of innovative cancer therapies. It offers a comprehensive portfolio of therapeutics and diagnostics to improve the treatment and cure of cancer patients worldwide. The company is divided into different divisions to enable effective development of cancer therapies, including research and development, production, marketing, and distribution of cancer drugs. The research and development department of OncoTherapy Science Inc. consists of a team of scientists and researchers who focus on identifying new therapeutic targets and developing innovative therapeutics. The research department has already made significant advances in the field of personalized medicine. OncoTherapy Science Inc. provides a wide range of products to offer better therapy options for cancer patients, including innovative antibody-based therapeutics, including immunotherapies, cytokines, antibody conjugates, mono- and polyclonal antibodies. The company also works on the development of diagnostics to enhance the effectiveness of therapy options, offering tests and diagnostic instruments that improve the accuracy of diagnosis and help patients choose the best possible therapy option. OncoTherapy Science Inc. also has a production department that utilizes modern technologies and automated production lines. The production facilities are set up according to the latest GMP standards to ensure that the products are of the highest quality and purity and comply with FDA regulations. The company markets and distributes its products worldwide through a network of partners and distributors. It has branches in different countries and collaborations with leading research institutions and universities around the world to support its research and development. In summary, OncoTherapy Science Inc. is a company focused on the research, development, and marketing of cancer therapeutics and diagnostics. It aims to provide better treatment options for cancer patients worldwide and has already made significant progress. With its wide range of innovative products, modern production facility, and strong research and development program, OncoTherapy Science Inc. is a leading company in cancer research and therapy.

The revenue cannot currently be calculated for OncoTherapy Science.

The profit cannot currently be calculated for OncoTherapy Science.

The P/E ratio cannot be calculated for OncoTherapy Science at the moment.

The P/S cannot be calculated for OncoTherapy Science currently.

The Eulerpool Quality Score for OncoTherapy Science is 2/10.

The ISIN of OncoTherapy Science is JP3202150003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of OncoTherapy Science is 726692. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of OncoTherapy Science is 4564.T. The ticker symbol is used to trade OncoTherapy Science shares on the stock exchange.

OncoTherapy Science paid dividends every year for the past 0 years.

OncoTherapy Science is assigned to the 'Health' sector.

The dividends of OncoTherapy Science are distributed in JPY.

All fundamentals and in-depth analysis of OncoTherapy Science

Our stock analysis for OncoTherapy Science stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoTherapy Science. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

OncoTherapy Science Stock
OncoTherapy Science Revenue→
OncoTherapy Science Stock
OncoTherapy Science Net Income→
OncoTherapy Science Stock
OncoTherapy Science P/E→
OncoTherapy Science Stock
OncoTherapy Science P/S→
OncoTherapy Science Stock
OncoTherapy Science EBIT→
OncoTherapy Science Stock
OncoTherapy Science Dividend→
OncoTherapy Science Stock
OncoTherapy Science Directors Dealings→
OncoTherapy Science Stock
OncoTherapy Science Stocks→
OncoTherapy Science Stock
OncoTherapy Science Market capitalization→
OncoTherapy Science Stock
OncoTherapy Science Debt→
OncoTherapy Science Stock
OncoTherapy Science Liabilities→
OncoTherapy Science Stock
OncoTherapy Science Equity→
OncoTherapy Science Stock
OncoTherapy Science AAQS→
OncoTherapy Science Stock
OncoTherapy Science Employees→
OncoTherapy Science Stock
OncoTherapy Science ROE→
OncoTherapy Science Stock
OncoTherapy Science ROA→
OncoTherapy Science Stock
OncoTherapy Science ROCE→
OncoTherapy Science Stock
OncoTherapy Science News→
OncoTherapy Science Stock
OncoTherapy Science Analyst Price Targets→

Health Stocks

Oncovista Innovative TherapiesOncotelic TherapeuticsOncozengeOncosil MedicalOndine BiomedicalOncoSec MedicalOne Health GroupOncopeptidesOne World ProductsOnconova TherapeuticsOnemednetOnconetixAll Stocks A–Z →